3-Oct-2024
CYC Signs Agreement with VA and First DoD Order Received
1-Oct-2024
Change of Director's Interest Notice - JW
3-Sep-2024
Cyclopharm - 2024 First Half Results & USA Expansion Update
29-Aug-2024
Webinar - 1H2024 Results and USA update
27-Aug-2024
Cyclopharm 2024 H1 Trading and USA Expansion Update
27-Aug-2024
Half Yearly Report and Accounts
28-Jun-2024
Cleansing Notice
28-Jun-2024
Application for quotation of securities - CYC
28-Jun-2024
Proposed issue of securities - CYC
28-Jun-2024
Change of Director's Interest Notice - KB
28-Jun-2024
Change of Director's Interest Notice - DH
28-Jun-2024
Change of Director's Interest Notice - DA
28-Jun-2024
Application for quotation of securities - CYC
27-Jun-2024
Appendix 3B
27-Jun-2024
Update - Proposed issue of securities - CYC
25-Jun-2024
Update - Proposed issue of securities - CYC
25-Jun-2024
Cyclopharm completes oversubscribed Share Purchase Plan
24-Jun-2024
USA Reimbursement Update for TECHNEGAS
19-Jun-2024
Cyclopharm Presenting at Macquarie Emerging Leaders Conf
11-Jun-2024
Change in substantial holding AACCF
11-Jun-2024
Change in substantial holding Chemical Overseas
11-Jun-2024
Change in substantial holding Barings
5-Jun-2024
Change in substantial holding from CVC
5-Jun-2024
TECHNEGAS Awarded US Pass-Through Reimbursemt Status
4-Jun-2024
Cleansing Statement - Placement
4-Jun-2024
Update - Application for quotation of securities - CYC
4-Jun-2024
CYC Results of AGM Poll - Addendum
3-Jun-2024
Change of Director's Interest Notice - GK
3-Jun-2024
Change in substantial holding
31-May-2024
Share Purchase Plan Offer Booklet
30-May-2024
Update - Application for quotation of securities - CYC
30-May-2024
Cleasing Statement - Placement
29-May-2024
Change of Director's Interest Notice - JW
29-May-2024
Application for quotation of securities - CYC
29-May-2024
CYC Results of AGM poll amended
27-May-2024
Notification of buy-back - CYC
27-May-2024
CYC Results of AGM poll
27-May-2024
Update - Proposed issue of securities - CYC
27-May-2024
Managing Director's AGM address
27-May-2024
CYC 2024 AGM Presentation
27-May-2024
Chairman's Address to Shareholders
27-May-2024
Cyclopharm Successfully Completes A$20.0 Million Placement
24-May-2024
Proposed issue of securities - CYC
24-May-2024
Cyclopharm Capital Raising
24-May-2024
Cyclopharm Capital Raising Presentation
24-May-2024
Trading Halt
16-May-2024
Appendix 3C Final buy-back notification
6-May-2024
Cyclopharm Business Update
26-Apr-2024
Becoming a substantial holder
26-Apr-2024
Notice of Annual General Meeting/Proxy Form
24-Apr-2024
Ceasing to be a substantial holder
8-Apr-2024
Application for quotation of securities - CYC
26-Mar-2024
Appendix 4G
26-Mar-2024
Annual Report to shareholders
25-Mar-2024
Voluntary Escrow Shares to be Released
25-Mar-2024
Date of Annual General Meeting
19-Mar-2024
First USA Patients Imaged with Technegas
1-Mar-2024
S&P DJI Announces March 2024 Quarterly Rebalance
28-Feb-2024
CYC Results Summary
28-Feb-2024
Preliminary Final Report
19-Feb-2024
CYC Board Changes
19-Feb-2024
Initial Director's Interest Notice
12-Feb-2024
Cyclopharm Appoints Jason Smith as CFO
6-Feb-2024
Cyclopharm to Present at Euroz Hartleys Healthcare Forum
5-Feb-2024
Cyclopharm Trading and USA Launch Update
29-Jan-2024
CYC and Yale Translational Research Partner on Technegas
5-Dec-2023
Cyclopharm Signs First USA Contract for Technegas
1-Dec-2023
Change of Director's Interest Notice
1-Dec-2023
Application for quotation of securities - CYC
15-Nov-2023
Technegas USA Commercialisation Update
2-Nov-2023
Change of Director's Interest Notice
1-Nov-2023
Change of Director's Interest Notice
5-Oct-2023
CYC USFDA Approval Webinar Presentation
3-Oct-2023
FDA Technegas Approval Webinar
3-Oct-2023
SNMMI Announcement Regarding USFDA Approval of Technegas
2-Oct-2023
Cyclopharm Receives USFDA Approval for Technegas
26-Sep-2023
Investor Presentation Correction
26-Sep-2023
Investor Presentation Correction
12-Sep-2023
Application for quotation of securities - CYC
25-Aug-2023
Litigation Update and Receipt of Settlement Payment
22-Aug-2023
Dividend/Distribution - CYC
22-Aug-2023
Half Year Accounts
9-Aug-2023
USFDA Approval Process Update
17-Jul-2023
Cyclopharm 2023 Half Year Accounts Update - Record Revenues
16-May-2023
Notification of buy-back - CYC
16-May-2023
Results of Meeting
16-May-2023
Managing Director's Address to Shareholders
16-May-2023
CYC 2023 AGM Presentation
16-May-2023
Chairman's Address to Shareholders
9-May-2023
Cyclopharm Confirms USFDA Scheduled Inspection Date
24-Apr-2023
USFDA Confirms Technegas Six Month Review Period
20-Apr-2023
Cyclopharm Acquires DuPharma ApS
18-Apr-2023
Application for quotation of securities - CYC
17-Apr-2023
Proposed issue of securities - CYC
13-Apr-2023
Notice of Annual General Meeting/Proxy Form
5-Apr-2023
Cyclopharm USFDA Approval Progress Update
31-Mar-2023
Appendix 4G
31-Mar-2023
Annual Report to shareholders
30-Mar-2023
Technegas Enters Final Six Month USFDA Review Cycle
24-Mar-2023
Application for quotation of securities - CYC
15-Mar-2023
Date of Annual General Meeting
20-Feb-2023
CYC Results Summary
20-Feb-2023
Preliminary Final Report
20-Feb-2023
Dividend/Distribution - CYC
5-Dec-2022
Change of Director's Interest Notice - KBarrow
30-Nov-2022
Change of Director's Interest Notice - DAngus
29-Nov-2022
Cyclopharm Receives $1.64m R&D Refund
9-Nov-2022
Bell Potter Healthcare Conference Directors Profile
9-Nov-2022
Bell Potter Healthcare Conference
5-Oct-2022
Notification of cessation of securities - CYC
27-Sep-2022
CYC Board Changes
27-Sep-2022
Initial Director's Interest Notice
1-Sep-2022
Initial Director's Interest Notice
1-Sep-2022
CYC Board Changes
17-Aug-2022
Half Year 2022 Results
17-Aug-2022
Half Yearly Report and Accounts
17-Aug-2022
Dividend/Distribution - CYC
7-Jul-2022
Technegas Used In Multicenter COVID Study
4-Jul-2022
1H 2022 Business Update - Record Revenues
14-Jun-2022
Change of Director's Interest Notice
24-May-2022
CYC Investor Presentation 24 May 2022
24-May-2022
Technegas used in Diagnosing Long COVID
23-May-2022
Change of Director's Interest Notice
17-May-2022
Results of Meeting
17-May-2022
Managing Director's Address to Shareholders
17-May-2022
CYC 2022 AGM Presentation
17-May-2022
Chairman's Address to Shareholders
14-Apr-2022
Notice of Annual General Meeting/Proxy Form
31-Mar-2022
Appendix 4G
31-Mar-2022
Annual Report to shareholders
16-Mar-2022
Date of Annual General Meeting
9-Mar-2022
Change of Director's Interest Notice
4-Mar-2022
S&P DJI Announces March 2022 Quarterly Rebalance
23-Feb-2022
CYC Results Summary
23-Feb-2022
Dividend/Distribution - CYC
23-Feb-2022
Preliminary Final Report
3-Feb-2022
Cyclopharm USFDA Update
24-Jan-2022
Cyclopharm Business Update
1-Dec-2021
Final Director's Interest Notice
1-Dec-2021
Board Update
9-Nov-2021
Bell Potter HealthCare Conference
28-Oct-2021
Jobkeeper Payments Notice
23-Aug-2021
Half Year 2021 Financial Results
23-Aug-2021
Dividend/Distribution - CYC
23-Aug-2021
Half Yearly Report and Accounts
10-Aug-2021
Initial Director's Interest Notice
10-Aug-2021
CYC Board Changes
2-Jul-2021
CYC First Half Trading Update
28-Jun-2021
Cyclopharm USFDA Update
7-Jun-2021
Ceasing to be a substantial holder from MUFG
4-Jun-2021
Ceasing to be a substantial holder from MS
4-Jun-2021
Becoming a substantial holder from MUFG
4-Jun-2021
Becoming a substantial holder from MS
3-Jun-2021
Ceasing to be a substantial holder from MUFG
2-Jun-2021
Ceasing to be a substantial holder from MS
1-Jun-2021
Becoming a substantial holder from MUFG
31-May-2021
Becoming a substantial holder from MS
26-May-2021
Ceasing to be a substantial holder from MUFG
25-May-2021
Ceasing to be a substantial holder from MS
24-May-2021
Becoming a substantial holder from MUFG
21-May-2021
Becoming a substantial holder from MS
20-May-2021
Ceasing to be a substantial holder from MUFG
20-May-2021
Ceasing to be a substantial holder from MS
19-May-2021
Becoming a substantial holder from MUFG
18-May-2021
Becoming a substantial holder from MS
18-May-2021
Ceasing to be a substantial holder from MUFG
18-May-2021
Ceasing to be a substantial holder from MS
13-May-2021
Becoming a substantial holder from MUFG
13-May-2021
Becoming a substantial holder from MS
11-May-2021
Ceasing to be a substantial holder from MUFG
10-May-2021
Ceasing to be a substantial holder from MS
7-May-2021
Becoming a substantial holder from MUFG
6-May-2021
Ceasing to be a substantial holder from MUFG
5-May-2021
Becoming a substantial holder from MS
4-May-2021
CYC Amended Constitution
4-May-2021
Results of Meeting
4-May-2021
Becoming a substantial holder from MUFG
4-May-2021
Ceasing to be a substantial holder from MUFG
4-May-2021
Managing Director's Address to Shareholders
4-May-2021
CYC 2021 AGM Presentation
4-May-2021
Chairman's Address to Shareholders
3-May-2021
Ceasing to be a substantial holder from MS
30-Apr-2021
Becoming a substantial holder from MS
29-Apr-2021
Ceasing to be a substantial holder from MS
20-Apr-2021
Becoming a substantial holder from MUFG
19-Apr-2021
Becoming a substantial holder from MS
19-Apr-2021
Ceasing to be a substantial holder from MUFG
16-Apr-2021
Ceasing to be a substantial holder from MS
15-Apr-2021
Becoming a substantial holder from MUFG
14-Apr-2021
Becoming a substantial holder from MS
30-Mar-2021
Notice of Annual General Meeting/Proxy Form
29-Mar-2021
Appendix 4G
29-Mar-2021
Annual Report to shareholders
26-Mar-2021
Change of Share Registry Details
12-Mar-2021
S&P DJI Announces March 2021 Quarterly Rebalance
12-Mar-2021
Confirmation of Technegas USFDA Timetable
8-Mar-2021
Change of Director's Interest Notice - DH
3-Mar-2021
Change of Director's Interest Notice - TM
3-Mar-2021
Date of Annual General Meeting
25-Feb-2021
CYC Results Summary
25-Feb-2021
Preliminary Final Report
25-Feb-2021
Dividend/Distribution - CYC
24-Feb-2021
Change of Director's Interest Notice DH
24-Feb-2021
Change of Director's Interest Notice TM
19-Feb-2021
Appendix 2A LTIP
19-Feb-2021
Appendix 2A SPP
17-Feb-2021
Appendix 3B - Amended
17-Feb-2021
Cyclopharm Announces Results of Share Purchase Plan Offer
10-Feb-2021
Change in substantial holding - Chemical Overseas
10-Feb-2021
Change in substantial holding - Barings
8-Feb-2021
Change in substantial holding
5-Feb-2021
Cyclopharm Receives $3.1M R&D Tax Incentive for FY2020
4-Feb-2021
Change in substantial holding from CVC
3-Feb-2021
Change of substantial shareholding from AEF
1-Feb-2021
Share Purchase Plan Offer Booklet
1-Feb-2021
Appendix 2A - Placement
1-Feb-2021
Cleansing Notice - Share Purchase Plan
1-Feb-2021
Cleansing Notice - Placement
29-Jan-2021
Change in substantial holding
29-Jan-2021
Change in substantial shareholding from AEF
25-Jan-2021
Proposed issue of Securities - CYC
25-Jan-2021
Cyclopharm Capital Raising Presentation
25-Jan-2021
Cyclopharm Successfully Completes A$30 Million Placement
22-Jan-2021
SNMMI Requests USFDA to Expedite Approval For Technegas
21-Jan-2021
Trading Halt
14-Jan-2021
USFDA Approval Progress for Technegas and Business Update
26-Nov-2020
Bell Potter Healthcare Conference
22-Oct-2020
Change of Director's Interest Notice TM
1-Oct-2020
Change of Director's Interest Notice
29-Sep-2020
Change of Director's Interest Notice
23-Sep-2020
Cyclopharm Investor Presentation
15-Sep-2020
Technegas USA Trial Successfully Meets Primary Endpoint
9-Sep-2020
CYC Partners With McMasters University In COVID-19 Research
25-Aug-2020
Half Year 2020 Financial Results
25-Aug-2020
Half Yearly Report and Accounts
25-Aug-2020
Dividend/Distribution - CYC
27-Jul-2020
Change of Director's Interest Notice
27-Jul-2020
Appendix 2A
9-Jul-2020
Results of Meeting
9-Jul-2020
Managing Director's Address to Shareholders
9-Jul-2020
CYC 2020 AGM Presentation
9-Jul-2020
Chairman's Address to Shareholders
7-Jul-2020
CYC 1H2020 Business Update
5-Jun-2020
Notice of Annual General Meeting/Proxy Form
29-May-2020
Technegas Approved in Russia - Clarification
27-May-2020
USFDA Approval to File Received for Technegas
26-May-2020
Technegas Approved in Russia
21-May-2020
Final share buy-back notice - Appendix 3F
6-May-2020
Form 484 cancellation of Long Term Incentive Plan shares
5-May-2020
Appendix 2A
14-Apr-2020
USFDA Grants Cyclopharm USD$2.9m Application Fee Waiver
31-Mar-2020
CYC Appendix 4G
31-Mar-2020
Annual Report to shareholders
30-Mar-2020
Cyclopharm Lodges NDA for Technegas with the USFDA
24-Mar-2020
Cyclopharm Company Update
17-Mar-2020
Change of Director's Interest Notice
17-Mar-2020
Change of Director's Interest Notice
13-Mar-2020
Change of Director's Interest Notice
3-Mar-2020
Cyclopharm Investor Presentation
2-Mar-2020
Change of Director's Interest Notice
26-Feb-2020
Preliminary Final Report
26-Feb-2020
Dividend/Distribution - CYC
15-Jan-2020
Change in substantial holding
15-Jan-2020
Change in substantial holding
13-Jan-2020
Change in substantial holding
3-Jan-2020
Becoming a substantial holder
2-Jan-2020
Change in substantial holding from CVC
2-Jan-2020
Change in substantial holding from AEF
31-Dec-2019
Becoming a substantial holder
31-Dec-2019
Appendix 3B
30-Dec-2019
Change of Director's Interest Notice
20-Dec-2019
CYC Institutional Placement - Premium To Share Price
20-Dec-2019
AGREEMENT TO UTILISE CYCLOTRON FACILITY ASSETS
19-Dec-2019
Trading Halt
19-Dec-2019
Pause in Trading
19-Dec-2019
Appendix 3B
12-Dec-2019
Change of Director's Interest Notice JM
12-Dec-2019
Appendix 3B
10-Dec-2019
CYC Business Update
27-Nov-2019
Final Director's Interest Notice
27-Nov-2019
Board Update
21-Oct-2019
Cyclopharm Investor Presentation - TechKnow Invest Roadshow
30-Sep-2019
Cyclopharm Strengthens Leadership Team
22-Aug-2019
CYC Half Yearly Reports and Accounts
22-Aug-2019
Dividend/Distribution - CYC
26-Jul-2019
Cyclopharm Investor Presentation - Bioshares 2019
27-Jun-2019
Change of Director's Interest Notice - TM
13-Jun-2019
Change of Director's Interest Notice - TM
31-May-2019
Appendix 3B LTIP
27-May-2019
Change of Director's Interest Notice
27-May-2019
Appendix 3B
21-May-2019
Announcement of buy-back - Appendix 3C
21-May-2019
Results of Meeting
21-May-2019
Managing Director's Address to Shareholders
21-May-2019
CYC 2019 AGM Presentation
21-May-2019
Chairman's Address to Shareholders
20-May-2019
Final share buy-back notice - Appendix 3F
18-Apr-2019
Notice of General Meeting/Proxy Form
4-Apr-2019
Cyclopharm Investor Presentation
3-Apr-2019
Change of Director's Interest Notice
29-Mar-2019
CYC Appendix 4G
29-Mar-2019
Annual Report to shareholders
27-Feb-2019
Dividend/Distribution - CYC
27-Feb-2019
Preliminary Final Report
24-Jan-2019
CYC Update - R&D Tax Incentive, USFDA, German Litigation
19-Dec-2018
CANM Endorses Technegas
29-Oct-2018
CYC - FNN Interview
12-Oct-2018
Positive USFDA Meeting - Technegas sales expected in 2019
9-Oct-2018
CYC Form 484 Cancellation of Long Term Incentive Plan shares
17-Sep-2018
Change of Director's Interest Notice VG
17-Sep-2018
Response to ASX Appendix 3Y Query
12-Sep-2018
Change of Director's Interest Notice VG
4-Sep-2018
Cyclopharm FNN Investor Event
23-Aug-2018
Dividend/Distribution - CYC
23-Aug-2018
CYC Half Yearly Reports and Accounts
13-Aug-2018
Change in substantial holding from CVC
10-Aug-2018
Change in substantial holding from AEF
8-Aug-2018
Cyclopharm 2018 First Half Preliminary Headline Update
2-Jul-2018
Appendix 3B LTIP
28-Jun-2018
Change of Director's Interest Notice
27-Jun-2018
Change of Director's Interest Notice - Amended
26-Jun-2018
Change of Director's Interest Notice
14-Jun-2018
Change in substantial holding from CVC
13-Jun-2018
Change in substantial holding from AEF
29-May-2018
Announcement of buy-back - Appendix 3C
29-May-2018
Results of Meeting
29-May-2018
CYC 2018 AGM Presentation
29-May-2018
Managing Director's Address to Shareholders
29-May-2018
Chairman's Address to Shareholders
28-May-2018
Final share buy-back notice - Appendix 3F
17-May-2018
Better Defining Airways Disease with Technegas
7-May-2018
Cyclopharm Acquires Scandinavian Distribution Business
27-Apr-2018
Notice of Annual General Meeting/Proxy Form
29-Mar-2018
40 Patient Milestone Achieved For Technegas USFDA Trial
26-Mar-2018
CYC Appendix 4G
26-Mar-2018
Annual Report to shareholders
15-Mar-2018
2017 Results Presentation
1-Mar-2018
Change of Director's Interest Notice - David Heaney
26-Feb-2018
CYC Reports Solid FY2017 Results - Maintains Dividend
26-Feb-2018
Preliminary Final Report
26-Feb-2018
Dividend/Distribution - CYC
21-Dec-2017
FNN Interview and Presentation
12-Dec-2017
Cyclopharm FNN Investor Event
20-Nov-2017
Change of Director's Interest Notice - D Heaney
18-Oct-2017
CYC CEO Presentation 2017 Australian Microcap Conference
26-Sep-2017
Technegas USFDA Clinical Trial - Patient Enrolment Underway
20-Sep-2017
Cyclopharm acquires European distribution business
19-Sep-2017
Advancing Molecular Imaging in NSW
8-Sep-2017
Form 484 - cancellation of Long Term Incentive Plan shares
28-Aug-2017
Cyclopharm Limited 1H2017 Results Investor Presentation
28-Aug-2017
Dividend/Distribution - CYC
18-Aug-2017
Nuclear imaging trial aiming to clear up airway diagnosis
21-Jul-2017
CYC CEO To Present at Bioshares 2017 Biotech Conference
6-Jul-2017
Change in substantial holding - Chemical Trustee Limited
6-Jul-2017
Change in substantial holding - Barings Acceptance Limited
4-Jul-2017
Change in substantial holding from CVC
4-Jul-2017
Change in substantial holding from AEF
4-Jul-2017
Change of Director's Interest Notice - JMcBrayer
4-Jul-2017
Change of Director's Interest Notice - VGould
4-Jul-2017
Change of Director's Interest Notice - D Heaney
30-Jun-2017
Appendix 3B Final
28-Jun-2017
CYC Entitlement Offer Closed
28-Jun-2017
CYC Notification of Shortfall
14-Jun-2017
CYC Entitlement Offer Booklet
5-Jun-2017
Letter to Ineligible Shareholders
5-Jun-2017
Letter to Eligible Shareholders
5-Jun-2017
Appendix 3B
5-Jun-2017
Cleansing Statement
5-Jun-2017
Entitlement Offer
2-Jun-2017
Response to ASX query on Appendix 3Y
1-Jun-2017
CYC - Positive Results of China Clinical Trial
31-May-2017
Change of Director's Interest Notice
12-May-2017
CYC May 2017 Investor Presentation
9-May-2017
Announcement of buy-back - Appendix 3C
9-May-2017
Results of Meeting
9-May-2017
Managing Director's Address to Shareholders
9-May-2017
Chairman's Address to Shareholders
9-May-2017
CYC 2017 AGM Presentation
8-May-2017
Final share buy-back notice - Appendix 3F
19-Apr-2017
Appendix 3B
7-Apr-2017
Notice of Annual General Meeting/Proxy Form
3-Apr-2017
Initial Director's Interest Notice
29-Mar-2017
CYC Board Changes
28-Mar-2017
CYC Appendix 4G
17-Mar-2017
Change in substantial holding from CVC
9-Mar-2017
Becoming a substantial holder - AACCF (Amended)
6-Mar-2017
CYC 2016 Financial Year Results Investor Presentation
1-Mar-2017
Ceasing to be a substantial holder - Lloyds (Amended)
27-Feb-2017
Cyclopharm Amended 2016 Preliminary Financial Report
22-Feb-2017
Dividend/Distribution - CYC
22-Feb-2017
Preliminary Final Report
17-Feb-2017
Becoming a substantial holder - AACCF
17-Feb-2017
Ceasing to be a substantial holder - Lloyds
6-Feb-2017
CYC 2016 PRELIMINARY HEADLINE UPDATE-RECORD RESULTS
1-Feb-2017
Release Date of 2016 Full Year Preliminary Financial Results
25-Nov-2016
Change of Director's Interest Notice
23-Nov-2016
CYC Achieves USFDA Agreement For Technegas Trial Design
31-Oct-2016
Change of Company Address
20-Oct-2016
Becoming a substantial holder from AEF
19-Oct-2016
Cyclopharm CEO Microcap Investment Conference Presentation
13-Oct-2016
Cyclopharm Business Update on Significant Milestones
7-Oct-2016
Chairman to Stand Down Temporarily
29-Aug-2016
CYC Share Registry Details
24-Aug-2016
Cyclopharm Limited 1H2016 Results Investor Presentation
19-Aug-2016
Dividend/Distribution - CYC
29-Jul-2016
CEO Presentation at BioShares BioTech Summit 2016
26-Jul-2016
Appendix 3B LTIP
21-Jul-2016
Cyclopharm Investor Presentation 21 July 2016
14-Jul-2016
CYC Strengthens Mgt Depth and Expands Clinical Expertise
28-Jun-2016
Change of Director's Interest Notice
28-Jun-2016
Change of Director's Interest Notice
27-Jun-2016
CYC Signs Agreement with the Canadian Association of Nuc Med
21-Jun-2016
Trading Update & Record Technegas Order Received from China
30-May-2016
Change of Share Registry address
11-May-2016
Announcement of buy-back - Appendix 3C
11-May-2016
Board Changes / Appendix 3Z
11-May-2016
Results of Annual General Meeting
11-May-2016
Managing Director's Report
11-May-2016
Managing Director's AGM Presentation
11-May-2016
Chairman's Address to Shareholders
10-May-2016
Cyclopharm to Proceed Independently with FDA Trials
18-Apr-2016
Appendix 4G
8-Apr-2016
Notice of Annual General Meeting/Proxy Form
17-Mar-2016
Cyclopharm Limited Investor Presentation
24-Feb-2016
Dividend/Distribution - CYC
24-Feb-2016
Strong Technegas Earnings Underpin Record Profit
24-Feb-2016
Preliminary Final Report
29-Jan-2016
Technegas COPD Trial Update
31-Dec-2015
Cyclopharm receives insurance settlement
31-Dec-2015
Cyclopharm receives insurance settlement
26-Nov-2015
Response to ASX query re Appendix 3Y
26-Nov-2015
Change of Director's Interest Notice
5-Nov-2015
Change of Director's Interest Notice
26-Oct-2015
Change of Director's Interest Notice
22-Oct-2015
Change in substantial holding from CVC
22-Oct-2015
Change of Director's Interest Notice
19-Oct-2015
Change of Director's Interest Notice
14-Oct-2015
Cyclopharm Pays Maiden Dividend
12-Oct-2015
Change of Director's Interest Notice
12-Oct-2015
Cyclopharm Launches World-First Nuclear Medicine Technology
7-Oct-2015
CYC Investor Presentation 7 October 2015
6-Oct-2015
Change of Director's Interest Notice
1-Oct-2015
Change of Director's Interest Notice
25-Sep-2015
Change of Director's Interest Notice
24-Sep-2015
Change of Director's Interest Notice
21-Sep-2015
Change of Director's Interest Notice
18-Sep-2015
Change in substantial holding from CVC
17-Sep-2015
Change of Director's Interest Notice
14-Sep-2015
Managing Director's Address to Investors
14-Sep-2015
Cyclopharm signs Term Sheet with Jubilant Draximage
27-Aug-2015
Dividend/Distribution - CYC
26-Aug-2015
Cyclopharm Unveils Inaugural Dividend
27-Jul-2015
CYC Investor Presentation July 2015
14-Jul-2015
Change of Director's Interest Notice
14-Jul-2015
Appendix 3B
10-Jul-2015
Change of Share Registry Name
26-May-2015
Results of Meeting
26-May-2015
Managing Director's Report
26-May-2015
Managing Director's AGM Presentation
26-May-2015
Chairman's Address to Shareholders
24-Apr-2015
Notice of Annual General Meeting/Proxy Form
12-Mar-2015
Investor Presentation
19-Feb-2015
Cyclopharm Reports Record Profit
19-Feb-2015
Preliminary Final Report
4-Feb-2015
Response to ASX Query
29-Jan-2015
Change of Director's Interest Notice
29-Jan-2015
Change of Director's Interest Notice
21-Jan-2015
Change of Share Registry address
27-Nov-2014
Form 484 - cancellation of Long Term Incentive Plan shares
27-Nov-2014
Form 484 Cancellation of Long Term Incentive Plan shares
16-Sep-2014
Update on Cyclotron Facility
2-Sep-2014
Appendix 3B
26-Aug-2014
Results of Mediation
14-Jul-2014
Change of Director's Interest Notice
20-Jun-2014
Cyclotron Facility Suffers Significant Water Damage
22-May-2014
Results of Meeting
22-May-2014
Managing Director's Report
22-May-2014
Chairman's Address to Shareholders
22-May-2014
Managing Director's AGM Presentation
15-May-2014
Chairman Reinstated
22-Apr-2014
Notice of Annual General Meeting/Proxy Form
31-Mar-2014
2013 Annual Report
28-Mar-2014
Cyclopharm to cease Cyclotron commercial operations
25-Mar-2014
Change of Director's Interest Notice
20-Mar-2014
Change of Director's Interest Notice
6-Mar-2014
Amended Appendix 3X
5-Mar-2014
Change of Director's Interest Notice
28-Feb-2014
Preliminary Final Report
23-Dec-2013
Change of Director's Interest Notice
25-Oct-2013
Japanese Regulatory Approval received
24-Oct-2013
Chairman to Stand Down Temporarily
21-Oct-2013
Change of Director's Interest Notice
17-Oct-2013
Letter to shareholders
14-Oct-2013
Change of Director's Interest Notice
19-Sep-2013
Change of Director's Interest Notice
16-Sep-2013
Director Appointment/Resignation
12-Sep-2013
Change of Director's Interest Notice
10-Sep-2013
Change of Director's Interest Notice
9-Sep-2013
Change of Director's Interest Notice
29-Aug-2013
Change of Director's Interest Notice
28-Aug-2013
2013 Half Yearly Report and Accounts
15-Aug-2013
Change of Director's Interest Notice
22-Jul-2013
Change of Director's Interest Notice
18-Jul-2013
Change of Director's Interest Notice
11-Jul-2013
Change of Director's Interest Notice
1-Jul-2013
Change of Director's Interest Notice
24-Jun-2013
Change of Director's Interest Notice
13-Jun-2013
Change of Director's Interest Notice
6-Jun-2013
Change of Director's Interest Notice
6-Jun-2013
MMI Research Revolutionises The Study of Ancient Artefacts
15-May-2013
Results of Meeting
15-May-2013
Managing Director's AGM Presentation
15-May-2013
Managing Director's Report
15-May-2013
Chairman's Address to Shareholders
3-May-2013
Change in substantial holding
2-May-2013
Technegas May Facilitate Earlier Diagnosis of COPD
18-Apr-2013
Cyclopharm Develops New Nuclear Medicine Technology
15-Apr-2013
Notice of Annual General Meeting/Proxy Form
4-Apr-2013
Change of Director's Interest Notice
2-Apr-2013
Form 484 - cancellation of Long Term Incentive Plan shares
28-Mar-2013
Annual Report to shareholders
26-Mar-2013
Change of Director's Interest Notice
26-Feb-2013
Preliminary Final Report
27-Dec-2012
Change in substantial holding
18-Dec-2012
Change of Director's Interest Notice
18-Dec-2012
Change of Director's Interest Notice
14-Dec-2012
Despatch of Holding Statements
14-Dec-2012
Appendix 3B Rights Issue
23-Nov-2012
Rights Issue - Despatch of Offer Documents
19-Nov-2012
Technegas Clinical Trial - First Patient Enrolled
9-Nov-2012
Entitlement and Acceptance Form
9-Nov-2012
Offer Booklet
9-Nov-2012
Cleansing Notice
9-Nov-2012
Appendix 3B
9-Nov-2012
Letter to Ineligible Shareholders
9-Nov-2012
Letter to Eligible Shareholders
9-Nov-2012
Renounceable Issue
6-Nov-2012
Change of Director's Interest Notice
6-Nov-2012
Change of Director's Interest Notice
6-Nov-2012
Change of Director's Interest Notice
6-Nov-2012
Appendix 3B
6-Nov-2012
Change of Director's Interest Notice
20-Sep-2012
Change in substantial holding
30-Aug-2012
Half Yearly Report and Accounts
28-Jun-2012
Cyclopharm Files Claim Against ANSTO
8-Jun-2012
Update on Share Consolidation
28-May-2012
AGM Presentation Audio Broadcast
24-May-2012
Results of Annual General Meeting
24-May-2012
Managing Director's Report
24-May-2012
Chairman's Address
24-May-2012
AGM Presentation
23-Apr-2012
Notice of Annual General Meeting/Proxy Form
4-Apr-2012
ANSTO Subsidiary in breach of Competitive Neutrality Rules
27-Mar-2012
Annual Report to shareholders
5-Mar-2012
Director Appointment/Resignation
29-Feb-2012
Preliminary Final Report
13-Feb-2012
Change in substantial holding
28-Dec-2011
Change in substantial holding
19-Dec-2011
MUH becomes Shareholder in CYC Imaging Joint Venture
19-Dec-2011
Change of Director's Interest Notice
19-Dec-2011
Change of Director's Interest Notice
13-Dec-2011
Cyclopharm Receives Approval from United States FDA
12-Dec-2011
Correction - Number of Issued Shares
9-Dec-2011
Rights Issue - Despatch of Holding Statements
6-Dec-2011
Completion of Rights Issue and Notice of Under Subscriptions
18-Nov-2011
Entitlement and Acceptance Form
18-Nov-2011
Offer Booklet for Renounceable Rights Issue
17-Nov-2011
Cleansing Notice
4-Nov-2011
Unmarketable Parcel Sale Facility
4-Nov-2011
Appendix 3B
4-Nov-2011
Letter to Ineligible Shareholders
4-Nov-2011
Letter to Eligible Shareholders
4-Nov-2011
Renounceable Rights Issue and Sale of Unmarketable Parcels
3-Nov-2011
Renewal of Debt Facility with National Australia Bank
27-Sep-2011
Amended Change of Director's Interest Notice
23-Sep-2011
Change of Director's Interest Notice
31-Aug-2011
Half Yearly Report and Accounts
29-Jul-2011
Trading Update
27-Jul-2011
Director Appointment/Resignation
27-Jun-2011
Change in substantial holding
20-Jun-2011
Change of Registered Office Address
6-Jun-2011
Change in substantial holding
2-Jun-2011
AGM Presentation Audio Broadcast
26-May-2011
AGM Presentation
26-May-2011
Managing Director's Report
26-May-2011
Chairman's Address to Shareholders
5-May-2011
Initial Director's Interest Notice
29-Apr-2011
Director Appointment/Resignation
18-Apr-2011
Notice of General Meeting/Proxy Form
25-Mar-2011
Company Secretary Appointment/Resignation
25-Mar-2011
Annual Report to shareholders
28-Feb-2011
Preliminary Final Report
22-Feb-2011
Clinical Protocol Approval from US FDA
24-Dec-2010
Diversity Policy
24-Dec-2010
Share Trading Policy
16-Dec-2010
Cyclopet sells commercial FDG doses
13-Dec-2010
Change of Director's Interest Notice
3-Dec-2010
Cyclopet receives TGA License
16-Nov-2010
Change in substantial holding
31-Aug-2010
Half Yearly Report and Accounts
6-Jul-2010
Company Update
26-May-2010
Change of Director`s Interest Notice
25-May-2010
Regulatory Approval in China
24-May-2010
2010 AGM Presentation - Audio Broadcast
20-May-2010
Results of Meeting
20-May-2010
Chairman`s Address
20-May-2010
Managing Director`s Presentation
20-May-2010
AGM Presentation
30-Apr-2010
Change in substantial holding
15-Apr-2010
Notice of General Meeting/Proxy Form
18-Mar-2010
2009 Annual Report
25-Feb-2010
Preliminary Final Report
17-Dec-2009
Change of Director`s Interest Notice
11-Dec-2009
Cyclopharm settles claim for US$1.8m
25-Nov-2009
Change in substantial holding from CVC
12-Nov-2009
Change of Director`s Interest Notice
9-Nov-2009
Cyclotron delivered to Macquarie University Hospital
19-Oct-2009
Change of Director`s Interest Notice
14-Oct-2009
Response to an ASX Query - Director`s Interest Notices
6-Oct-2009
Change of Director`s Interest Notice
29-Sep-2009
Change of Director`s Interest Notice
24-Sep-2009
Change of Director`s Interest Notice
27-Aug-2009
2009 Half Yearly Report and Accounts
3-Aug-2009
CYC enters into Medical Imaging JV- Audio Broadcast
29-Jul-2009
Cyclopharm enters into Medical Imaging Joint Venture
30-Jun-2009
Change of Director`s Interest Notice
9-Jun-2009
Change of Director`s Interest Notice
25-May-2009
2009 AGM Presentation - Audio Broadcast
21-May-2009
Results of Meeting
21-May-2009
Chairman`s Address
21-May-2009
Managing Director`s Presentation
21-May-2009
AGM Presentation
28-Apr-2009
Company Update
20-Apr-2009
Notice of General Meeting/Proxy Form
26-Mar-2009
2008 Annual Report
17-Mar-2009
Full Year Presentation - Audio Broadcast
17-Mar-2009
Change of Director`s Interest Notice
3-Mar-2009
Full Year Presentation
3-Mar-2009
Final Director`s Interest Notice
26-Feb-2009
Preliminary Final Report
20-Feb-2009
Profit Upgrade
19-Feb-2009
Resignation of Director
21-Jan-2009
Change in substantial holding
13-Jan-2009
Change in substantial holding from CVC
22-Dec-2008
Lodgement of application to sell Technegas in United States
22-Dec-2008
Company Update
4-Dec-2008
Change of Director`s Interest Notice
4-Dec-2008
Change of Director`s Interest Notice
4-Dec-2008
Change of Director`s Interest Notice
2-Dec-2008
Change of Director`s Interest Notice
2-Dec-2008
Change of Director`s Interest Notice
28-Nov-2008
Allotment of Rights Issue Shares
21-Nov-2008
Closure of Rights Issue
30-Oct-2008
Amendment to Dispatch Rights Issue Offer Document
30-Oct-2008
Rights Issue - Dispatch Offer Document
30-Oct-2008
Rights Issue - Offer Document
30-Oct-2008
Rights Issue - Cleansing Statement
17-Oct-2008
Amended Appendix 3B
17-Oct-2008
Amended Rights Issue Timetable
16-Oct-2008
Appendix 3B
16-Oct-2008
Announcement of Offer
26-Sep-2008
Change in substantial holding
24-Sep-2008
Investor Presentation - Audio Broadcast
17-Sep-2008
Investor Presentation
22-Aug-2008
Half Year Presentation
22-Aug-2008
2008 Half Yearly Report and Accounts
16-Jul-2008
Government expands PET approved indications
5-Jun-2008
Initial Director`s Interest Notice
5-Jun-2008
Appendix 3B
5-Jun-2008
Change of Director`s Interest Notice
3-Jun-2008
Change in substantial holding
3-Jun-2008
Confirmation of appointment of new Managing Director
27-May-2008
2008 AGM Presentation - Audio Broadcast
21-May-2008
Cyclopharm receives regulatory approval in Brazil
20-May-2008
Change of Director`s Interest Notice
12-May-2008
Change of Director`s Interest Notice
2-May-2008
AGM Presentation
2-May-2008
Results of Meeting
28-Apr-2008
Change in substantial holding
2-Apr-2008
Change of Director`s Interest Notice
2-Apr-2008
Amended Appendix 3Y released 25 March 2008
28-Mar-2008
Change in substantial holding
26-Mar-2008
Notice of Annual General Meeting/Proxy Form
25-Mar-2008
Change of Director`s Interest Notice
25-Mar-2008
Change in substantial holding
19-Mar-2008
Annual Report to shareholders
14-Mar-2008
Cyclopharm Limited achieves a major milestone in Sydney
6-Mar-2008
Full Year Result and Company Update - Audio Broadcast
29-Feb-2008
Preliminary Final Report
1-Feb-2008
Cyclopharm makes its first sale in Russia
25-Jan-2008
Director Appointment/Resignation
7-Jan-2008
Cyclopharm achieves a major milestone
3-Jan-2008
Regulatory Approval in Italy
17-Oct-2007
Change in substantial holding from CVC
16-Oct-2007
Change of Director`s Interest Notice
18-Sep-2007
Change of Director`s Interest Notice
28-Aug-2007
Half Year Presentation
28-Aug-2007
2007 Half Yearly Report and Accounts
13-Aug-2007
Change of Director`s Interest Notice
10-Aug-2007
Change in substantial holding from CVC
2-Aug-2007
Change in substantial holding from CVC
29-Jun-2007
Change in substantial holding
29-Jun-2007
Appendix 3B
13-Jun-2007
Change of Director's Interest Notice
9-May-2007
Managing Directors AGM Presentation
9-May-2007
Minutes of AGM
9-May-2007
Notice of Annual General Meeting
2-Apr-2007
2006 Annual Report
26-Feb-2007
Preliminary Final Report
13-Feb-2007
Becoming a substantial holder
12-Feb-2007
Initial Director's Interest Notice
12-Feb-2007
Initial Director's Interest Notice
12-Feb-2007
Initial Director's Interest Notice
12-Feb-2007
Initial Director's Interest Notice
12-Feb-2007
Initial Director's Interest Notice